Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05512208 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
A Phase 2 study of Solid Tumor and Cervical Cancer, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 4
- Study locations
NCT05512208: Recruiting Phase 2 study of Solid Tumor and Cervical Cancer, sponsored by University of Oklahoma.
NCT05512208 is a Phase 2 study of Solid Tumor and Cervical Cancer that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 55 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (75% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05512208, a Phase 2 study of Solid Tumor and Cervical Cancer, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.
Primary Outcome
To evaluate the efficacy of Avutometinib (VS-6766) + defactinib in endometrioid, MOC, HGSOC and solid gynecological cancer patients with RAS/BRAF/NF1 mutations on confirmed overall response rate (ORR; partial response \[PR\] + complete response \[CR\] defined according to RECIST 1.1) as assessed by the investigator.
Conditions Studied
Interventions
- DRUG Avutometinib (VS-6766) + defactinib
Study Locations (4)
Florida
- AdventHealth - Orlando
Louisiana
- Louisiana State University Medical Center New Orleans - New Orleans
New Mexico
- University of New Mexico Comprehensive Cancer Center - Albuquerque
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2023-02-06 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
What NCT05512208 shows while recruiting
NCT05512208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (75% lower).
The record links to 5 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Avutometinib (VS-6766) + defactinib is the first listed.
NCT05512208 reports a single indexed study location in Florida, Louisiana, New Mexico.
Frequently Asked Questions
What is clinical trial NCT05512208 about?
NCT05512208 is a clinical study titled "A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib". The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.
What is the current status of trial NCT05512208?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2023-02-06. Estimated completion is 2029-12.
What conditions does trial NCT05512208 study?
This clinical trial studies the following conditions: Solid Tumor, Cervical Cancer, High-grade Serous Ovarian Cancer, Endometrioid Cancer, Mucinous Ovarian Cancer.
What interventions are being tested in trial NCT05512208?
The interventions under investigation include: Avutometinib (VS-6766) + defactinib (DRUG).
Who is sponsoring clinical trial NCT05512208?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05512208 being conducted?
This trial has 4 study locations across Florida, Louisiana, New Mexico, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05512208's enrollment target sits among peer trials
55 115th of 196 higher than 81 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
RECRUITING · Phase 2
-
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RECRUITING · Phase 2
-
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
RECRUITING · Phase 2
-
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI